These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 29596514

  • 1. Characterisation of insulin analogues therapeutically available to patients.
    Adams GG, Meal A, Morgan PS, Alzahrani QE, Zobel H, Lithgo R, Kok MS, Besong DTM, Jiwani SI, Ballance S, Harding SE, Chayen N, Gillis RB.
    PLoS One; 2018; 13(3):e0195010. PubMed ID: 29596514
    [Abstract] [Full Text] [Related]

  • 2. Identification of recombinant human insulin and biosynthetic insulin analogues by multiplexed targeted unlabeled mass spectrometry of proteotypic tryptic peptides.
    Qasem RJ, Aldawsari AS, Almutairi FE, Alsadoon AS.
    J Pharm Biomed Anal; 2019 Aug 05; 172():357-363. PubMed ID: 31096094
    [Abstract] [Full Text] [Related]

  • 3. Development and validation of a method for quantification of human insulin and its synthetic analogues in plasma and post-mortem sera by LC-MS/HRMS.
    Bottinelli C, Nicoli R, Bévalot F, Cartiser N, Roger C, Chikh K, Kuuranne T, Fanton L, Guitton J.
    Talanta; 2021 Apr 01; 225():122047. PubMed ID: 33592769
    [Abstract] [Full Text] [Related]

  • 4. Effects of phenol and meta-cresol depletion on insulin analog stability at physiological temperature.
    Teska BM, Alarcón J, Pettis RJ, Randolph TW, Carpenter JF.
    J Pharm Sci; 2014 Aug 01; 103(8):2255-67. PubMed ID: 24909933
    [Abstract] [Full Text] [Related]

  • 5. Glargine and degludec: Solution behaviour of higher dose synthetic insulins.
    Adams GG, Alzahrani Q, Jiwani SI, Meal A, Morgan PS, Coffey F, Kok S, Rowe AJ, Harding SE, Chayen N, Gillis RB.
    Sci Rep; 2017 Aug 04; 7(1):7287. PubMed ID: 28779138
    [Abstract] [Full Text] [Related]

  • 6. Investigation of the Physico-Chemical Properties that Enable Co-Formulation of Basal Insulin Degludec with Fast-Acting Insulin Aspart.
    Havelund S, Ribel U, Hubálek F, Hoeg-Jensen T, Wahlund PO, Jonassen I.
    Pharm Res; 2015 Jul 04; 32(7):2250-8. PubMed ID: 25563978
    [Abstract] [Full Text] [Related]

  • 7. Solution structures of long-acting insulin analogues and their complexes with albumin.
    Ryberg LA, Sønderby P, Barrientos F, Bukrinski JT, Peters GHJ, Harris P.
    Acta Crystallogr D Struct Biol; 2019 Mar 01; 75(Pt 3):272-282. PubMed ID: 30950398
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Doping control analysis of insulin and its analogues in equine urine by liquid chromatography-tandem mass spectrometry.
    Ho EN, Wan TS, Wong AS, Lam KK, Stewart BD.
    J Chromatogr A; 2011 Feb 25; 1218(8):1139-46. PubMed ID: 21256494
    [Abstract] [Full Text] [Related]

  • 10. Safety of insulin analogues as compared with human insulin in pregnancy.
    Toledano Y, Hadar E, Hod M.
    Expert Opin Drug Saf; 2016 Jul 25; 15(7):963-73. PubMed ID: 27145344
    [Abstract] [Full Text] [Related]

  • 11. Cross-reactivity of insulin analogues with three insulin assays.
    Dayaldasani A, Rodríguez Espinosa M, Ocón Sánchez P, Pérez Valero V.
    Ann Clin Biochem; 2015 May 25; 52(Pt 3):312-8. PubMed ID: 25172526
    [Abstract] [Full Text] [Related]

  • 12. Pharmacotherapy for hyperglycemia in pregnancy - The new insulins.
    Toledano Y, Hadar E, Hod M.
    Diabetes Res Clin Pract; 2018 Nov 25; 145():59-66. PubMed ID: 29730391
    [Abstract] [Full Text] [Related]

  • 13. Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function.
    Hartmann T, Overhagen S, Ouwens DM, Raschke S, Wohlfart P, Tennagels N, Wronkowitz N, Eckel J.
    Cardiovasc Diabetol; 2016 Jul 15; 15():96. PubMed ID: 27422524
    [Abstract] [Full Text] [Related]

  • 14. Nasal absorption of mixtures of fast-acting and long-acting insulins.
    Pillion DJ, Fyrberg MD, Meezan E.
    Int J Pharm; 2010 Mar 30; 388(1-2):202-8. PubMed ID: 20080164
    [Abstract] [Full Text] [Related]

  • 15. [The new insulins].
    Krzentowski G.
    Rev Med Brux; 2005 Sep 30; 26(4):S241-5. PubMed ID: 16240869
    [Abstract] [Full Text] [Related]

  • 16. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin.
    Jonassen I, Havelund S, Hoeg-Jensen T, Steensgaard DB, Wahlund PO, Ribel U.
    Pharm Res; 2012 Aug 30; 29(8):2104-14. PubMed ID: 22485010
    [Abstract] [Full Text] [Related]

  • 17. The quaternary structure of insulin glargine and glulisine under formulation conditions.
    Nagel N, Graewert MA, Gao M, Heyse W, Jeffries CM, Svergun D, Berchtold H.
    Biophys Chem; 2019 Oct 30; 253():106226. PubMed ID: 31376619
    [Abstract] [Full Text] [Related]

  • 18. [New developments in the treatment and monitoring of type 1 diabetes mellitus].
    Otto-Buczkowska E, Jarosz-Chobot P, Tucholski K.
    Endokrynol Pol; 2008 Oct 30; 59(3):246-53. PubMed ID: 18615401
    [Abstract] [Full Text] [Related]

  • 19. Determination of human insulin and its analogues in human blood using liquid chromatography coupled to ion mobility mass spectrometry (LC-IM-MS).
    Thomas A, Schänzer W, Thevis M.
    Drug Test Anal; 2014 Oct 30; 6(11-12):1125-32. PubMed ID: 25219675
    [Abstract] [Full Text] [Related]

  • 20. Insulin degludec. Uncertainty over cardiovascular harms.
    Prescrire Int; 2014 Jun 30; 23(150):149. PubMed ID: 25121146
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.